In addition, the study demonstrated that bispecific antibodies targeting LAG-3 and PD-L1 elicit an effective anti-tumor response from immune cells in the tumor microenvironment, although these results further support the potential of targeting LAG-3 as a cancer immunotherapy. Here, LAG3 is linked to neoplasm.